Uplistings can help a firm increase its visibility as well as enhance liquidity. This clinical-stage biopharma company just announced a successful uplift. Peak Bio, Inc. (OTC PK: PKBO) is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical needs for patients with inflammatory, rare-specialty diseases and cancer. In a press release today, the company announced a successful up-listing from the OTC Pink Market to the OTCQB® Venture Market, effective for trading at today’s open. Peak Bio will continue to trade under the ticker symbol “PKBO.”
Through the uplist, Peak Bio believes that the move will provide enhanced investor benefits, including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements due to the OTCQB increased transparency, reporting standards, management certification and compliance requirements.
Shares were trading up at $0.472 in morning trade.
Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
]]>